Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07426484 · ClinicalTrials.gov registry record · Phase 4
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
A Phase 4 study, sponsored by Dana-Farber Cancer Institute.
- Not yet
- Registry status
- Phase 4
- Development phase
- 80
- Enrollment target
NCT07426484 is a Phase 4 study that has not yet begun recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 80 participants.
The verdict
NCT07426484, a Phase 4 study, has not yet begun recruiting, sponsored by Dana-Farber Cancer Institute.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 80 participants
- Enrollment target
Study Summary
This is study is to evaluate the safety and efficacy of cosibelimab in special populations with advanced cutaneous squamous cell carcinoma (CSCC). The name of the drug involved in this research study is: -cosibelimab (a type of an anti-PD-L1 antibody)
Interventions
- DRUG Sirolimus
- DRUG Everolimus
- DRUG Prednisone
- DRUG Cosibelimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2026-07 |
| Est. Completion | 2032-12-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07426484
The ClinicalTrials.gov registry entry for NCT07426484 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Sirolimus is the first listed.
NCT07426484 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07426484 about?
NCT07426484 is a clinical study titled "Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy". This is study is to evaluate the safety and efficacy of cosibelimab in special populations with advanced cutaneous squamous cell carcinoma (CSCC). The name of the drug involved in this research study is: -cosibelimab (a type of an anti-PD-L1 antibody)
What is the current status of trial NCT07426484?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2026-07. Estimated completion is 2032-12-15.
What interventions are being tested in trial NCT07426484?
The interventions under investigation include: Sirolimus (DRUG), Everolimus (DRUG), Prednisone (DRUG), Cosibelimab (DRUG).
Who is sponsoring clinical trial NCT07426484?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.